Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 1, 2012, Pages 69-73

  Lee, Bun Hee ^a   Kang, Seung Gul ^c   Kim, Tae Woo ^d   Lee, Heon Jeong ^e   Yoon, Ho Kyoung ^e   Park, Young Min ^b  

^a KARF Hospital   (South Korea)

^b Inje University   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Eumseong Somang Hospital   (South Korea)

^e Korea University College of Medicine   (South Korea)

Author keywords

amisulpride; antipsychotics; hyperprolactinemia; prolactin

Indexed keywords

AMISULPRIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PROLACTIN;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; HYPERPROLACTINEMIA; KOREA; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PROLACTIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT;

EID: 84862950065     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2011.02296.x     Document Type: Article

References (25)

1. Byerly M, Suppes T, Tran QV, Baker RA,. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J. Clin. Psychopharmacol. 2007; 27: 639-661. (Pubitemid 351339452)
2. Johnsen E, Kroken RA, Abaza M, Olberg H, JÃrgensen HA,. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J. Clin. Psychopharmacol. 2008; 28: 686-690.
3. Schoemaker H, Claustre Y, Fage D, et al,. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 1997; 280: 83-97. (Pubitemid 27171391)
4. Leucht S, Pitschel-Walz G, Engel RR, Kissling W,. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 2002; 159: 180-190. (Pubitemid 34126893)
5. Scatton B, Claustre Y, Cudennec A, et al,. Amisulpride: from animal pharmacology to therapeutic action. Int. Clin. Psychopharmacol. 1997; 12 (Suppl.): S29-S36. (Pubitemid 27286568)
6. Danion JM, Rein W, Fleurot O,. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am. J. Psychiatry 1999; 156: 610-616. (Pubitemid 29162984)
7. Martinot JL, PaillÃre-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, MaziÃre B,. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996; 124: 154-158. (Pubitemid 26112784)
8. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM,. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
9. Lee BH, Kim YK,. Resolution of amisulpride-associated amenorrhea by switching to aripiprazole. Psychiatry Invest. 2006; 3: 102-106.
10. Kopecek M, Bares M, Svarc J,. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol. Lett. 2004; 25: 419-422. (Pubitemid 40227970)
11. Lee BH, Kim YK, Park SH,. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog. Neuropsychopharmacol Biol. Psychiatry 2006; 30: 714-717.
12. Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C,. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog. Neuropsychopharmacol Biol. Psychiatry 2007; 31: 92-96. (Pubitemid 44959254)
13. Raj R, Sidhu BS,. Hyperprolactinaemia with amisulpride. Indian J. Psychiatry 2008; 50: 54-56.
14. Jaber M, Robinson S, Missale C, Caron M,. Dopamine receptors and brain function. Neuropharmacology 1996; 35: 1503-1519. (Pubitemid 27026480)
15. Kapur S, Langlois X, Vinken P, Megens A, Coster RD, Andrews J,. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 2002; 302: 1129-1134. (Pubitemid 34920235)
16. Bressan R, Erlandsson K, Spencer E, Ell P, Pilowsky L,. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004; 175: 367-373. (Pubitemid 39361925)
17. Serri O, Chik CL, Ur E, Ezzat S,. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169: 575-581. (Pubitemid 37174600)
18. Famini P, Maya MM, Melmed S,. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J. Clin. Endocrinol. Metab. 2011; 96: 1633-1641.
19. Bahceci M, Sismanoglu A, Ulug U,. Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol. Endocrinol. 2010; 26: 505-508.
20. Lee BH, Kim YK,. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog. Neuropsychopharmacol Biol. Psychiatry 2006; 30: 658-662.
21. Kleinberg DL, Davis JM, deCoster R, Van-Baelen B, Brecher M,. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 1999; 19: 57-61. (Pubitemid 29047332)
22. American Psychiatric Association (ed.). Practice Guidelines for the Treatment of Patients with Schizophrenia. American Psychiatric Association, Washington, DC, 2004.
23. Eberhard J, Lindström E, Holstad M, Levander S,. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr. Scand. 2007; 115: 268-276. (Pubitemid 46425745)
24. Compton MT, Miller AH,. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol. Bull. 2002; 36: 143-164.
25. Walters J, Jones I,. Clinical questions and uncertainty-prolactin measurement in patients with schizophrenia and bipolar disorder. J. Psychopharmacol. 2008; 22: 82-89.